ATE433993T1 - Modulatorische verbindungen und verfahren für glutamattransport - Google Patents
Modulatorische verbindungen und verfahren für glutamattransportInfo
- Publication number
- ATE433993T1 ATE433993T1 AT04714617T AT04714617T ATE433993T1 AT E433993 T1 ATE433993 T1 AT E433993T1 AT 04714617 T AT04714617 T AT 04714617T AT 04714617 T AT04714617 T AT 04714617T AT E433993 T1 ATE433993 T1 AT E433993T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- modulatory compounds
- glutamate transport
- protein expression
- eaat
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45022703P | 2003-02-26 | 2003-02-26 | |
| PCT/US2004/005698 WO2004076675A2 (en) | 2003-02-26 | 2004-02-25 | Glutamate transport modulatory compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE433993T1 true ATE433993T1 (de) | 2009-07-15 |
Family
ID=32927622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04714617T ATE433993T1 (de) | 2003-02-26 | 2004-02-25 | Modulatorische verbindungen und verfahren für glutamattransport |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060121488A1 (de) |
| EP (1) | EP1611238B1 (de) |
| JP (1) | JP2006524637A (de) |
| KR (1) | KR20050115245A (de) |
| AT (1) | ATE433993T1 (de) |
| AU (1) | AU2004214938B2 (de) |
| CA (1) | CA2516619A1 (de) |
| DE (1) | DE602004021574D1 (de) |
| DK (1) | DK1611238T3 (de) |
| ES (1) | ES2328811T3 (de) |
| MX (1) | MXPA05009134A (de) |
| PL (1) | PL377896A1 (de) |
| WO (1) | WO2004076675A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040191803A1 (en) * | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
| US20070238717A1 (en) * | 2003-10-21 | 2007-10-11 | Johns Hopkins University | Neuroprotection with Beta-Lactam Compounds |
| WO2006096404A2 (en) * | 2005-03-04 | 2006-09-14 | Alsgen, Inc | Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues |
| PT2982372T (pt) * | 2005-04-05 | 2020-10-09 | Univ Yale | Agentes moduladores do glutamato no tratamento de distúrbios mentais |
| EP1983988A2 (de) * | 2006-02-16 | 2008-10-29 | The McLean Hospital Corporation | Verfahren und zusammensetzungen zur behandlung von morbus parkinson |
| FR2902010B1 (fr) * | 2006-06-12 | 2008-08-22 | Pierre Fabre Medicament Sa | Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique |
| WO2009033055A1 (en) * | 2007-09-06 | 2009-03-12 | Rutgers, The State University Of New Jersey | Methods and kits for identification of anti-excitotoxic compounds |
| US20110201668A1 (en) * | 2008-01-30 | 2011-08-18 | Korea Institute Of Science And Technology | Regulation of neurotransmitter release through anion channels |
| JP5850321B2 (ja) * | 2010-02-10 | 2016-02-03 | 公立大学法人横浜市立大学 | 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用 |
| FR2958664B1 (fr) | 2010-04-07 | 2012-10-26 | Coatex Sas | Utilisation d'un latex de styrene et de taille de 100 nm comme agent rheologique dans une sauce de couchage papetiere, sauce et son procede d'obtention |
| US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| WO2012075408A1 (en) * | 2010-12-02 | 2012-06-07 | Massachusetts Institute Of Technology | Chemical and rnai suppressors of neurotoxicity in huntington's disease |
| EP2919816B1 (de) * | 2012-11-14 | 2019-03-27 | Daniel Offen | Kombinationsbehandlung für amyotrophe lateralsklerose (als) |
| US10448862B2 (en) * | 2013-09-06 | 2019-10-22 | Covidien Lp | System and method for light based lung visualization |
| CN104074095A (zh) * | 2014-06-25 | 2014-10-01 | 宁波天源科技有限公司 | 流变改质剂 |
| KR101809379B1 (ko) * | 2016-10-13 | 2017-12-14 | 연세대학교 산학협력단 | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
| CN111116374B (zh) * | 2019-12-04 | 2020-12-15 | 北京理工大学 | 一种氨鲁米特与2-硝基苯甲酸合成π-π键共晶体的方法 |
| CN110923148B (zh) * | 2019-12-11 | 2021-05-14 | 华北制药股份有限公司 | 青霉素v钾高产菌及其在发酵生产青霉素v钾中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4575506A (en) * | 1983-11-03 | 1986-03-11 | Zambon S.P.A. | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics |
| US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
| EP0543919B1 (de) * | 1990-08-13 | 1996-04-10 | G.D. Searle & Co. | Verwendung von heterozyklischen aminoalkoholverbindungen zur herstellung eines medikaments für die behandlung von erkrankungen des zns |
| US5658782A (en) * | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
| US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
| US6255467B1 (en) * | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
| US7060457B2 (en) * | 1998-03-18 | 2006-06-13 | Johns Hopkins University | Aberrant glutamate transporters and methods of use |
| JP2002515480A (ja) * | 1998-05-15 | 2002-05-28 | ユニバーシティ オブ バーモント | １６−ヒドロキシエイコサテトラエン酸の新規アナログ |
| US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
| CA2746824A1 (en) * | 1999-08-16 | 2001-01-22 | Revaax Pharmaceuticals, Llc | Neurotherapeutic composition and method |
| US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
| US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
| US6248360B1 (en) * | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
| AU2001288792A1 (en) * | 2000-09-06 | 2002-03-22 | Neurotherapeutics, Llc | Method of treating neurologic disorders |
| US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
| ATE420176T1 (de) * | 2002-02-15 | 2009-01-15 | Univ Johns Hopkins | Der eaat2-promotor und dessen verwendung |
| US20040191803A1 (en) * | 2002-11-22 | 2004-09-30 | Michela Gallagher | Target for therapy of cognitive impairment |
-
2004
- 2004-02-25 KR KR1020057015591A patent/KR20050115245A/ko not_active Application Discontinuation
- 2004-02-25 DE DE602004021574T patent/DE602004021574D1/de not_active Expired - Lifetime
- 2004-02-25 AU AU2004214938A patent/AU2004214938B2/en not_active Ceased
- 2004-02-25 CA CA002516619A patent/CA2516619A1/en not_active Abandoned
- 2004-02-25 US US10/546,860 patent/US20060121488A1/en not_active Abandoned
- 2004-02-25 EP EP04714617A patent/EP1611238B1/de not_active Expired - Lifetime
- 2004-02-25 WO PCT/US2004/005698 patent/WO2004076675A2/en active Application Filing
- 2004-02-25 PL PL377896A patent/PL377896A1/pl not_active Application Discontinuation
- 2004-02-25 JP JP2006503879A patent/JP2006524637A/ja active Pending
- 2004-02-25 AT AT04714617T patent/ATE433993T1/de not_active IP Right Cessation
- 2004-02-25 MX MXPA05009134A patent/MXPA05009134A/es active IP Right Grant
- 2004-02-25 ES ES04714617T patent/ES2328811T3/es not_active Expired - Lifetime
- 2004-02-25 DK DK04714617T patent/DK1611238T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004214938B2 (en) | 2008-11-06 |
| MXPA05009134A (es) | 2005-12-05 |
| DE602004021574D1 (de) | 2009-07-30 |
| ES2328811T3 (es) | 2009-11-18 |
| DK1611238T3 (da) | 2009-10-26 |
| EP1611238B1 (de) | 2009-06-17 |
| US20060121488A1 (en) | 2006-06-08 |
| KR20050115245A (ko) | 2005-12-07 |
| CA2516619A1 (en) | 2004-09-10 |
| EP1611238A2 (de) | 2006-01-04 |
| JP2006524637A (ja) | 2006-11-02 |
| WO2004076675A3 (en) | 2005-03-17 |
| EP1611238A4 (de) | 2007-07-04 |
| WO2004076675A2 (en) | 2004-09-10 |
| AU2004214938A1 (en) | 2004-09-10 |
| PL377896A1 (pl) | 2006-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE433993T1 (de) | Modulatorische verbindungen und verfahren für glutamattransport | |
| CY1123535T1 (el) | Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας | |
| WO2020102741A8 (en) | Methods and compositions for protein sequencing | |
| CY1110923T1 (el) | Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων | |
| CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
| EA201490735A1 (ru) | Лечение дегенеративного заболевания сустава | |
| BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| DK1680507T3 (da) | Bakterieekspression af proteaseinhibitorer og varianter deraf | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| ATE476654T1 (de) | Plattform für protein-profiling | |
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| BRPI0411854A (pt) | veìculos protéicos para vacinas | |
| DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine | |
| CY1110381T1 (el) | Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων | |
| DE602004026912D1 (de) | Formulierungen und verfahren zum denaturieren von proteinen | |
| ATE440860T1 (de) | An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen | |
| MXPA03000316A (es) | Reactivos y metodos para la identificacion de agentes de enlace. | |
| ATE545658T1 (de) | Verfahren zur behandlung von synovialsarkom | |
| ATE470195T1 (de) | Hohlraum-induzierte allosterische modifikation von intermolekularen interaktionen und verfahren zur identifikation von verbindungen, die diese bewirken. | |
| EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
| ATE332916T1 (de) | Farbstoff-markiertes peptid und dessen verwendung zur diagnostik | |
| DE602004016006D1 (de) | Screening-verfahren | |
| AR128224A1 (es) | Compuestos y métodos para tratar la ataxia de friedreich | |
| ZA202304030B (en) | Modified cxcl10 for immunotherapy of cancer diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1611238 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |